The Effects of Corneal Collagen Cross-linking

Corneal Ectasia Disorders Including Keratoconus Clinical Trial

Official title:

Phase III Study of Corneal Collagen Cross-linking Using Two Different Techniques.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT01708538
• Other study ID #: Rush CXL
• Status: Recruiting
• Phase: Phase 3
• Start date: October 2012
• Est. completion date: October 2024

Study information

• Verified date: October 2022
• Source: Rush Eye Associates
• Contact: Sloan W Rush, MD
• Phone: 806-353-0125
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The corneal collagen cross-linking treatment has been used with increasing success to treat corneal dystrophies such as "keratoconus." Recent advances have allowed different techniques for performing this cross-linking treatment. This study investigates the effects of corneal cross-linking using different surgical techniques.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: October 2024
• Est. primary completion date: October 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 10 Years to 70 Years

Eligibility

Inclusion Criteria:

• Age 10-70, willing to participate, diagnosis of corneal ectasia disorder

Exclusion Criteria:

• Unwilling or unable to participate in trial

Related Conditions & MeSH terms

• Corneal Ectasia Disorders Including Keratoconus
• Keratoconus

Intervention

Drug:
• CXL
corneal crosslinking

Locations

Country	Name	City	State
United States	Rush Eye Associates	Amarillo	Texas

Sponsors (1)

Lead Sponsor	Collaborator
Rush Eye Associates

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Visual acuity	Best corrected Snellen acuity	1 year
Primary	Keratometry measurements	Average curvature of the cornea	1 year